ZafGen Scores $14M Series B


Anti-obesity drug developer ZafGen closed a Series B financing worth $14 million, PE Hub reports, citing a regulatory filing. Third Rock Ventures and Atlas Venture supplied the funding for the Cambridge, MA-based startup, which Luke profiled in September.

By posting a comment, you agree to our terms and conditions.